Detalhe da pesquisa
1.
SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling.
Nat Immunol
; 23(11): 1588-1599, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36266363
2.
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
Mol Cancer
; 23(1): 97, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38730427
3.
A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.
J Transl Med
; 22(1): 190, 2024 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38383458
4.
Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer.
BMC Cancer
; 24(1): 424, 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38580900
5.
Small cell lung cancer: Subtypes and therapeutic implications.
Semin Cancer Biol
; 86(Pt 2): 543-554, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35398266
6.
Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer.
Oncologist
; 28(8): e625-e632, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37085156
7.
Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy.
Cancer Immunol Immunother
; 72(7): 2067-2074, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36795122
8.
TSAFinder: exhaustive tumor-specific antigen detection with RNAseq.
Bioinformatics
; 38(9): 2422-2427, 2022 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35191489
9.
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
J Natl Compr Canc Netw
; 21(11): 1164-1171.e5, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37935100
10.
Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules.
Br J Cancer
; 127(12): 2154-2165, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36253524
11.
Psychological Symptom Trajectories and Non-Small Cell Lung Cancer Survival: A Joint Model Analysis.
Psychosom Med
; 84(2): 215-223, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34629425
12.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(2): 198-211, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33476593
13.
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
J Natl Compr Canc Netw
; 19(8): 915-921, 2021 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33878726
14.
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
N Engl J Med
; 376(25): 2415-2426, 2017 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28636851
15.
Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
Cancer Immunol Immunother
; 69(11): 2403-2408, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32728772
16.
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications.
BMC Cancer
; 20(1): 383, 2020 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32375706
17.
Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.
BMC Cancer
; 19(1): 353, 2019 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30987609
18.
Safety of dose-reduced pemetrexed in patients with renal insufficiency.
J Oncol Pharm Pract
; 25(5): 1125-1129, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29871545
19.
The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
Mol Carcinog
; 56(2): 515-526, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27312358
20.
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
Lancet Oncol
; 17(12): 1661-1671, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27825638